$5.88 Billion is the total value of Avoro Capital Advisors LLC's 41 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 25.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | Buy | HORIZON THERAPEUTICS PLC | $1,001,629,000 | +1.6% | 9,295,000 | +3.3% | 17.05% | +10.1% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $744,452,000 | -15.8% | 5,075,000 | +1.5% | 12.67% | -8.8% |
| UTHR | Buy | UNITED THERAPEUTICS CORP | $655,803,000 | +18.4% | 3,035,000 | +1.2% | 11.16% | +28.3% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $404,507,000 | +145.5% | 8,555,555 | +71.1% | 6.88% | +165.9% |
| ARGX | Buy | ARGENX SEsponsored adr | $337,933,000 | +18.2% | 965,000 | +2.0% | 5.75% | +28.1% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $281,406,000 | +21.7% | 3,125,000 | +25.0% | 4.79% | +31.9% |
| ASND | Buy | ASCENDIS PHARMAsponsored adr | $269,060,000 | -14.7% | 2,000,000 | +1.0% | 4.58% | -7.6% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $247,380,000 | +70.7% | 2,800,000 | +49.3% | 4.21% | +85.0% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $213,675,000 | +26.6% | 18,500,000 | +4.6% | 3.64% | +37.1% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $182,299,000 | +13.6% | 1,075,000 | +26.5% | 3.10% | +23.1% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $165,606,000 | -21.0% | 8,675,000 | +2.1% | 2.82% | -14.4% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $155,731,000 | +179.2% | 4,985,000 | +36.6% | 2.65% | +202.5% |
| ISEE | Buy | IVERIC BIO INC | $121,220,000 | +5.1% | 7,250,000 | +2.1% | 2.06% | +13.9% |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $120,755,000 | +6.2% | 1,425,000 | 0.0% | 2.06% | +15.1% | |
| XBI | New | SPDR SERIES TRUST - S&P BIOTECHetf | $117,558,000 | – | 1,050,000 | +100.0% | 2.00% | – |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $114,781,000 | -43.7% | 1,235,000 | -63.9% | 1.95% | -39.0% |
| GLUE | MONTE ROSA THERAPEUTICS INC | $67,619,000 | +10.8% | 3,311,434 | 0.0% | 1.15% | +20.1% | |
| KURA | KURA ONCOLOGY INC | $56,000,000 | -25.3% | 4,000,000 | 0.0% | 0.95% | -19.0% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $51,348,000 | +40.5% | 2,200,000 | 0.0% | 0.87% | +52.3% | |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $47,611,000 | +61.3% | 2,175,000 | +40.8% | 0.81% | +74.6% |
| AADI BIOSCIENCES INC | $44,180,000 | -17.8% | 1,829,402 | 0.0% | 0.75% | -10.9% | ||
| MRSN | MERSANA THERAPEUTICS INC | $42,296,000 | -34.0% | 6,800,000 | 0.0% | 0.72% | -28.5% | |
| MNKD | MANNKIND CORP | $38,456,000 | +0.5% | 8,800,000 | 0.0% | 0.65% | +8.8% | |
| MARINUS PHARMACEUTICALS INC | $38,432,000 | +4.4% | 3,235,000 | 0.0% | 0.65% | +13.1% | ||
| PRAX | Buy | PRAXIS PRECISION MEDICINES INC | $35,066,000 | +18.5% | 1,780,000 | +11.2% | 0.60% | +28.4% |
| DSGN | Buy | DESIGN THERAPEUTICS INC | $35,029,000 | +62.4% | 1,636,100 | +11.4% | 0.60% | +75.8% |
| KYMR | Buy | KYMERA THERAPEUTICS INC | $34,920,000 | +30.4% | 550,000 | +20.7% | 0.59% | +41.1% |
| CBAY | CYMABAY THERAPEUTICS INC | $34,814,000 | -7.4% | 10,300,000 | 0.0% | 0.59% | +0.3% | |
| PMVP | Sell | PMV PHARMACEUTICALS INC | $33,842,000 | -61.2% | 1,465,000 | -49.9% | 0.58% | -57.9% |
| KRYS | New | KRYSTAL BIOTECH INC | $33,226,000 | – | 475,000 | +100.0% | 0.56% | – |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $29,237,000 | +3.2% | 1,230,000 | +7.0% | 0.50% | +11.9% |
| AMRN | AMARIN CORP PLCsponsored adr | $20,220,000 | -33.9% | 6,000,000 | 0.0% | 0.34% | -28.5% | |
| Sell | NUVALENT INC | $18,431,000 | -17.3% | 1,102,671 | -12.3% | 0.31% | -10.3% | |
| TANGO THERAPEUTICS INC | $16,957,000 | -15.4% | 1,550,000 | 0.0% | 0.29% | -8.3% | ||
| Sell | DICE THERAPEUTICS INC | $14,237,000 | -45.7% | 562,500 | -29.7% | 0.24% | -41.3% | |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCsponsored adr | $13,494,000 | -39.5% | 1,670,000 | -26.6% | 0.23% | -34.3% |
| ADVM | ADVERUM BIOTECHNOLOGIES INC | $12,232,000 | -18.9% | 6,950,000 | 0.0% | 0.21% | -12.2% | |
| New | IO BIOTECH INC | $10,243,000 | – | 2,055,883 | +100.0% | 0.17% | – | |
| GNCA | GENOCEA BIOSCIENCES INC | $5,898,000 | -39.6% | 5,084,184 | 0.0% | 0.10% | -34.6% | |
| FENC | Sell | FENNEC PHARMACEUTICALS INC | $5,280,000 | -66.4% | 1,200,000 | -28.1% | 0.09% | -63.6% |
| SRPT | Buy | SAREPTA THERAPEUTICS INCcall | $2,910,000 | +32.6% | 300,000 | +50.0% | 0.05% | +47.1% |
| XLRN | Exit | ACCELERON PHARMA INCcall | $0 | – | -476,100 | -100.0% | -0.00% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INCcall | $0 | – | -1,515,000 | -100.0% | -0.02% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INCcall | $0 | – | -650,000 | -100.0% | -0.02% | – |
| MRUS | Exit | MERUS N V | $0 | – | -450,000 | -100.0% | -0.16% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -84,000 | -100.0% | -0.37% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS INC | $0 | – | -1,068,000 | -100.0% | -0.57% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -5,700,000 | -100.0% | -1.57% | – | |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -664,000 | -100.0% | -1.89% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -4,000,000 | -100.0% | -10.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.